ALGS - Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1 AASLD Late Breaker Data | Benzinga
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Professor of Medicine at the Johns Hopkins University School of Medicine, to review the Late Breaking results and next steps for ALG-000184, its Phase 1 CAM-E drug candidate for chronic Hepatitis B (CHB), and the unmet need and current treatment landscape for patients with CHB on November 16, 2023 at 1:30 PM ET. To register, click here.
The Phase 1 data are being featured being featured in a late breaking poster session at the Liver Meeting® of the American Association of Liver Disease on November 13, 2023 (poster #5028-C).
A live question and answer will follow the formal presentation.
About Mark Sulkowski, MD
Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine.
Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to ...